Trial Condition(s):

Hypertension

Post-marketing Surveillance for hypertensive patients with diabetes and/or chronic kidney disease

Bayer Identifier:

15190

ClinicalTrials.gov Identifier:

NCT01363336

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This study is a post-marketing surveillance in Japan, and it is a local prospective, company sponsored and observational study of patient who have been treated by Adalat CR for hypertension with diabetes and/or chronic kidney disease. The objective of this study is to assess safety and efficacy profile of using Adalat CR in real clinical practice. A total 2,000 patients will be recruited and be observed for 6 months. Then, patient of whom microalbumin urea and serum creatinine are continuously monitored are additionally followed for 6 months.

Inclusion Criteria
- Patient who are administered with Adalat CR for hypertension with diabetes and/or chronic kidney disease (CKD)
Exclusion Criteria
- CKD with stage 5
 - CDK with dialysis

Trial Summary

Enrollment Goal
1882
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Adalat CC (Nifedipine, BAYA1040)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Japan

Status
Completed
 

Trial Design